Search

Copyright of Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu is the property of Chinese Journal of Tissue Engineering Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu is the property of Chinese Journal of Tissue Engineering Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Nonferrous Metals Engineering is the property of Beijing Research Institute of Mining & Metallurgy Technology Group and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

BACKGROUND: Allogeneic hematopoietic stem cell transplantation is an important or even the only method to cure a variety of hematological diseases. Herpes zoster virus infection after transplantation seriously affects the quality of life. OBJECTIVE: To explore the risk factors of varicella-zoster virus infection in patients after allogeneic hematopoietic stem cell transplantation, in order to reduce the incidence of varicella-zoster virus infection after allogeneic hematopoietic stem cell transplantation and the severity of the disease. METHODS: Clinical data of 654 patients who underwent allogeneic hematopoietic stem cell transplantation in the First Affiliated Hospital of Zhengzhou University from November 2016 to June 2021 were retrospectively analyzed to explore the related factors of the varicella-zoster virus infection after allogeneic hematopoietic stem cell transplantation. RESULTS AND CONCLUSION: 66 of the 654 patients developed varicella-zoster virus infection after allogeneic hematopoietic stem cell transplantation, and the morbidity was 10.1%. The average age of patients who infected with varicella-zoster virus was 21.5 (4-62) years old, and the average time of varicella-zoster virus infection was 149 days (19-1 179 days). The main manifestations were regional skin herpes, including 7 cases of herpes zoster encephalitis, 17 cases of post herpetic neuralgia, and 1 case of right ear deafness. The main treatments were topical use of ganciclovir gel, intravenous infusion of penciclovir, application of immunoglobulin to improve immune function and reduce the dosage of immunosuppressant. The median time of treatment was 11 days (3-38 days), and the herpes was scabbed or improved. Incidence of varicella-zoster virus infection after allogeneic hematopoietic stem cell transplantation was related to age (χ² = 7.816, P=0.005), whether fludarabine was used in the pretreatment scheme (χ² =5.004, P=0.025), whether there was cytomegalovirus infection (χ² =5.983, P=0.014), and the primary diseases (χ² =4.860, P=0.027). It was not related to the type of transplantation and the source of stem cells. The varicella-zoster virus infection is a common complication of allogeneic hematopoietic stem cell transplantation. It usually occurs within one year after transplantation. Patients with risk factors should pay more attention to prevention and treatment. Preventive application of antiviral drugs can reduce the incidence of varicella-zoster virus infection. [ABSTRACT FROM AUTHOR]

BACKGROUND: Allogeneic hematopoietic stem cell transplantation is an important or even the only potentially curative treatment for many hematological diseases. However, acute graft-versus-host disease is still one of the life-threatening complications after allogeneic hematopoietic stem cell transplantation. There is no standardized treatment for refractory acute graft-versus-host disease. Many studies indicated that mesenchymal stem cells may be used for treating acute graft-versus-host disease through the immunomodulatory effect; however, the actual effect is still to be confirmed. OBJECTIVE: To explore the efficacy and safety of human umbilical cord blood-derived mesenchymal stem cells in the treatment of refractory acute graft-versushost disease and the related factors for the efficacy. METHODS: Totally 24 patients who were diagnosed with refractory acute graft-versus-host disease patients and treated with third-party derived human umbilical cord blood-derived mesenchymal stem cells at the Hematopoietic Stem Cell Transplantation Center of the First Affiliated Hospital of Zhengzhou University were included in the present study. Among them, 8 cases were children, and 16 cases were adults; 10 cases were grade II acute graft-versus-host disease, and 14 cases were grades III-IV. The efficacy, adverse effects, recurrence of primary disease, secondary infection and long-term survival of these patients were observed. RESULTS AND CONCLUSION: (1) The median dose of total infused human umbilical cord blood-derived mesenchymal stem cells was 2.7×106/kg [(2.02- 6.00)×106/kg] with a median of 2.5 infusions (range, 2-6 times). The median time from the onset of acute graft-versus-host disease to first human umbilical cord blood-derived mesenchymal stem cells infusion was 12.5 days (range, 8-36 days). (2) The overall response rate at 28 days after infusion was 83% (20/24). The probability of 2-year overall survival was 33.3%. The 2-year overall survival for patients achieving complete remission and partial remission/non-remission were 57% and 0%, respectively (P < 0.000 1). There was significant difference between these two groups. (3) The efficacy for patients with grade II refractory acute graft-versus-host disease was better than grades III-IV (P=0.024). There was no remarkable difference in terms of age, involved organs, primary diseases and the number of infusions of human umbilical cord blood-derived mesenchymal stem cells. (4) In conclusion, treatment with human umbilical cord bloodderived mesenchymal stem cells is a safe and effective option for patients with refractory acute graft-versus-host disease. [ABSTRACT FROM AUTHOR]

Copyright of Chemistry & Industry of Forest Products is the property of Chemistry & Industry of Forest Products Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

BACKGROUND: The probability of obtaining sibling-matched hematopoietic stem cell transplantation donors for patients with severe aplastic anemia is less than 30%. With the recent improvement of unrelated peripheral blood stem cell transplantation, the efficacy of unrelated peripheral blood stem cell transplantation in the treatment of benign and malignant hematological diseases has reached a result similar to that of sibling-matched hematopoietic stem cell transplantation. OBJECTIVE: To evaluate the efficacy and safety of unrelated peripheral blood stem cell transplantation in the treatment of severe aplastic anemia. METHODS: A retrospective analysis was made in 25 severe aplastic anemia (type I and type II) patients who received unrelated peripheral blood stem cell transplantation from March 2014 to September 2019. All of them were sibling-matched hematopoietic stem cell transplantation-free patients who refused to accept immunosuppressive therapy. The transplantation pretreatment regimen was “fludarabine + cyclophosphamide + rabbit anti-human thymocyte globulin antibody”, and the prevention scheme of graft-versus-host disease was “cyclosporine + mycophenolate mofetil + short-term methotrexate”. The observation indicators included implantation rate, hematopoietic reconstitution time, incidence of graft-versus-host disease, incidence of transplantation-related complications, 5-year estimated overall survival rate and 5-year estimated disease-free survival rate. This study was approved by the Ethics Committee of the First Affiliated Hospital of Zhengzhou University. Patients and their family members signed the informed consent on unrelated peripheral blood stem cell transplantation. RESULTS AND CONCLUSION: (1) Three of the 25 patients died within 28 days after hematopoietic stem cell transplantation, and the implantation could not be evaluated. Of the remaining 22 patients, 21 cases (95.4%) obtained hematopoietic reconstitution and the implantation was successful; 1 case (4.6%) failed. The median time of neutrophil ≥ 0.5×109 L -1 and platelet ≥ 20×109 L -1 was 12 days (9-18 days) and 13 days (10-32 days), respectively. (2) Among the 21 patients with successful implantation, the incidence of acute graft-versus-host disease was 28.6% (6/21), including I-II degree in 3 cases and III–IV degree in 3 cases. There were only 9.5% patients with mild chronic graft-versus-host disease (2/21), and no moderate and severe chronic graft-versus-host disease occurred. (3) During the median follow-up of 396 days (15-1 886 days), 18 cases (72.0%) survived; the 5-year estimated overall survival rate was 71.1%; and the 5-year estimated disease-free survival rate was 65.6%. Totally 7 cases (28.0%) died, of which 3 cases (12.0%) died of infection, 2 cases (8.0%) died of acute intestinal graft-versus-host disease, 1 case (4.0%) died of intracranial hemorrhage, and 1 case (4.0%) died of multiple organ failure. (4) The results show that unrelated peripheral blood stem cell transplantation is a safe and effective treatment for severe aplastic anemia patients without sibling matching donor, and it is a feasible and useful alternative therapy. [ABSTRACT FROM AUTHOR]

Copyright of Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu is the property of Chinese Journal of Tissue Engineering Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chemistry & Industry of Forest Products is the property of Chemistry & Industry of Forest Products Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu is the property of Chinese Journal of Tissue Engineering Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu is the property of Chinese Journal of Tissue Engineering Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Application Research of Computers / Jisuanji Yingyong Yanjiu is the property of Application Research of Computers Edition and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Since the SLP( superword level parallel) algorithm could not efficiently deal with the large-scale applications which covered few parallel codes. This paper proposed and evaluated a new compile framework based on the improved SLP algorithm. It contained three phases. First.it tried to transform the non-isomorphic but similar instruction sequences to isomorphic instruction sequences by the improved algorithm as far as possible. Second .it took a global point of view of the target application when capturing the superwords reuse patterns before making the optimization decisions. Eventually.it combined data layout optimization for further performance improvement. Ibis paper did much experiment on the framework. Hie experimental results indicates that the optimization of the compile framework is better than SLP algorithm .the performance increases about 15.3%. [ABSTRACT FROM AUTHOR]